A transformative partnership between Lunit and Labcorp promises to accelerate digital pathology innovations through artificial intelligence. By combining Lunit’s expertise in AI-driven cancer diagnostics with Labcorp’s extensive laboratory services, the collaboration aims to support new breakthroughs in oncology research and clinical care.

BeOne Medicines ADR has received an IBD Relative Strength Rating upgrade, reflecting the stock’s improving price performance. This development positions the biotech-focused company under a brighter spotlight in the competitive pharma landscape.

Zymeworks recently surpassed a crucial threshold by earning a 90-plus IBD Relative Strength Rating, reflecting strong share-price performance. The biotech and pharmaceutical company now stands out in the industry for its notable momentum.

Arvinas, Inc., a clinical-stage biotechnology company specializing in targeted protein degradation, has announced its participation in two major investor conferences this November. From New Haven to London, Arvinas aims to present its progress to analysts, investors, and the broader scientific community via a live audio webcast.

VIVOLTA, a leading electrospun medical implant manufacturer, has unveiled a dedicated production facility at High Tech Campus Eindhoven. This expansion underscores the company’s commitment to advancing regenerative implants and boosting innovative healthcare solutions.

uniQure N.V. (QURE) is gaining bullish attention for its pioneering AMT-130 gene therapy, which some observers view as a groundbreaking approach to Huntington’s disease. With shares trading at $63.65 and a forward P/E of 27.93, investors see promise in the biotech’s innovative push toward a first-of-its-kind treatment.

Scientists have taken a curious concept once linked to an Ig Nobel prize and validated it in a human safety trial. Known as “butt-breathing” and formally called enteral ventilation, this technique might soon offer a new way to deliver oxygen.

In a newly revealed study, scientists have captured the first high-resolution 3D structure of a critical malaria parasite protein. Researchers believe this discovery may pave the way for significantly improved anti-malarial treatments.

DS-3939, a new therapy candidate, is showing encouraging early-stage results in a Phase 1/2 trial targeting advanced solid tumors. While full details remain behind a paywall, initial findings from a recent announcement suggest possibilities for future cancer treatment options.

A team of researchers at the Stanford School of Medicine claims to have discovered a gene responsible for a rare and startling ability: visualizing a murder by simply touching a missing person’s sweater. Their work sheds new light on a phenomenon previously shrouded in mystery.

Moran Wealth Management LLC has acquired 13,654 shares of CRISPR Therapeutics AG, reflecting the rising market confidence in the groundbreaking gene-editing field. The investment, worth approximately $664,000, highlights a continued uptick in institutional backing for CRISPR’s innovative biotech research.

Scientists in Vevey, Switzerland, are nurturing human mini-brains in nutrient-rich fluid, exploring a frontier called “wetware.” By blending biology with technology, they aim to uncover how organoid intelligence might change the landscape of artificial intelligence.

Scientists are investigating the remarkable secrets of supercentenarians, whose specialized gene—human bpifb4—could help treat Hutchinson-Gilford Progeria Syndrome (HGPS). The University of Bristol’s discovery offers hope for children with this rare genetic disease, which accelerates aging at an alarming rate.

Researchers at UTHealth Houston have made a significant leap toward decoding speech directly from the human brain. Their work, published in Nature Communications, points to a future where understanding silent thoughts and turning them into spoken words could become a reality.

Covington’s CTI, a biotech firm specializing in clinical research, was recently honored at the 11th annual Cincinnati Business Courier’s C-Suite Awards. Chief Operating Officer Jon Koch, Chief Financial Officer Brian Lawrence, and another Chief were recognized for their leadership, showcasing the firm’s contributions to the region’s thriving biotech sector.

ProSpecBio has unveiled a new Activin-A Recombinant Protein, aiming to advance crucial research into inflammation and brain injury. Announced in Rehovot, Israel, the product launch highlights growing interest in innovative tools to tackle pressing health issues.

Coya Therapeutics extended its congratulations to Dr. Shimon Sakaguchi, who received the Nobel Prize in Physiology or Medicine for his discovery of regulatory T cells and their role in immune function. The Houston-based organization praised this breakthrough for advancing our understanding of how the immune system is regulated.

Vektor Medical has secured a CE Mark for vMap, a non-invasive arrhythmia mapping solution. This development paves the way for European healthcare providers to utilize vMap’s capabilities in identifying and managing heart rhythm disorders.

A new investigation by The Schall Law Firm examines possible securities law violations by MoonLake Immunotherapeutics. Investors in the NASDAQ-listed company may have an opportunity to participate in a fraud claim if they believe they have been impacted by these allegations.

Mammotion’s robot lawn mowers let you maintain a pristine yard without manual effort. According to a recent Cnet report, you can take advantage of generous discounts—up to $1,100 off—to streamline your yard care routine.

Viridian Therapeutics has announced new inducement grants approved under Nasdaq Listing Rule 5635(c)(4). Released from Waltham, Mass. on October 2, 2025, this update highlights the company’s adherence to key regulatory requirements.